Brainstorm Cell Therapeutics Inc.Brainstorm Cell Therapeutics Inc.Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪37.65 M‬USD
−0.3251USD
‪−17.19 M‬USD
‪60.28 M‬
Beta (1Y)
3.74

About Brainstorm Cell Therapeutics Inc.

CEO
Chaim Lebovits
Headquarters
New York
Employees (FY)
29
Founded
2000
FIGI
BBG000FR6HQ1
Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of BCLI is 0.5290 USD — it has increased by 2.34% in the past 24 hours. Watch Brainstorm Cell Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Brainstorm Cell Therapeutics Inc. stocks are traded under the ticker BCLI.
BCLI stock has fallen by 16.20% compared to the previous week, the month change is a 2.40% fall, over the last year Brainstorm Cell Therapeutics Inc. has showed a 82.31% decrease.
BCLI reached its all-time high on Jan 7, 2005 with the price of 52.4738 USD, and its all-time low was 0.1340 USD and was reached on Oct 31, 2023. View more price dynamics on BCLI chart.
See other stocks reaching their highest and lowest prices.
BCLI stock is 6.31% volatile and has beta coefficient of 3.74. Track Brainstorm Cell Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Brainstorm Cell Therapeutics Inc. there?
Today Brainstorm Cell Therapeutics Inc. has the market capitalization of ‪36.22 M‬, it has decreased by 5.24% over the last week.
Yes, you can track Brainstorm Cell Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Brainstorm Cell Therapeutics Inc. is going to release the next earnings report on Aug 12, 2024. Keep track of upcoming events with our Earnings Calendar.
BCLI earnings for the last quarter are −0.05 USD per share, whereas the estimation was −0.07 USD resulting in a 28.57% surprise. The estimated earnings for the next quarter are −0.07 USD per share. See more details about Brainstorm Cell Therapeutics Inc. earnings.
Brainstorm Cell Therapeutics Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach 0 USD.
BCLI net income for the last quarter is ‪−3.40 M‬ USD, while the quarter before that showed ‪−5.58 M‬ USD of net income which accounts for 39.03% change. Track more Brainstorm Cell Therapeutics Inc. financial stats to get the full picture.
No, BCLI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 29, 2024, the company has 29.00 employees. See our rating of the largest employees — is Brainstorm Cell Therapeutics Inc. on this list?
Like other stocks, BCLI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Brainstorm Cell Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Brainstorm Cell Therapeutics Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Brainstorm Cell Therapeutics Inc. stock shows the sell signal. See more of Brainstorm Cell Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.